March 28, 2022
SIO Annual Scientific Meeting, March 24 -28, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 –...
Read More
March 11, 2022
2022 NYSE IPO Summit
Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from...
Read More
March 4, 2022
2022 St. Louis Dealmaker of the Year
The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of...
Read More
February 17, 2022
Immunophotonics Awarded $2.4 Million SBIR Grant by the National Cancer Institute
Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research...
Read More
February 2, 2022
Wei R. Chen B Cell Paper Publication
Hot off the press: Another part of the mechanism of action of how IP-001 (GC) remodels the tumor microenvironment revealed!...
Read More
January 19, 2022
SPIE Photonics West and BiOS Expo, Jan 22 – 27 in San Francisco
If you are interested in the interface between cancer immunotherapy innovation and photonics, then catch up with Tomas Hode, PhD,...
Read More
September 14, 2021
USPTO Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001
Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers...
Read More
September 7, 2021
Immunophotonics Switzerland (IPS Biopharma) Invited to Present at Swiss Biotech Day
Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day in the Emerging Company session hosted by BB...
Read More
September 1, 2021
Immunophotonics Publishes Follow-up Feature in Nature Biopharma Dealmakers
Immunophotonics is excited to be featured in the September 2021 oncology issue of Nature Biopharma Dealmakers. Read what Dr. Markus...
Read More
March 1, 2021
Immunophotonics Featured in Nature Biopharma Dealmakers
Immunophotonics has been featured in the March oncology issue of Nature Biopharma Dealmakers (www.nature.com/articles/d43747-021-00020-2 ). Nature selects only a handful...
Read More